Optimization of complex therapy of inflammatory diseases of women pelvic organs

А.М. Зиганшин, В.А. Мудров
In: Gynecology · 2019 · vol. 21(3) , pp. 30–34 · doi:10.26442/20795696.2019.3.190465 · W2972500112
article OA: gold CC0
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-10 ⓘ

This study evaluated Galavit as part of combination therapy for inflammatory pelvic organ diseases in women, finding it accelerated symptom relief and reduced complications compared to standard treatment.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-10 ⓘ

This open comparative study evaluated whether adding Galavit (aminodihydroftalazindione sodium) to standard therapy improves treatment outcomes in 120 women aged 18–44 hospitalized with acute or chronic exacerbation of salpingitis and oophoritis. Patients were randomized to receive Galavit on a specified intramuscular schedule or standard treatment alone, with outcomes assessed at admission, day 3, and discharge using clinical measures (including pain and fever), ultrasound inflammatory signs, and laboratory markers such as leukocytes, ESR, and leukocyte intoxication index. The main group showed faster improvement, with inflammation signs resolving on ultrasound more quickly and laboratory normalization occurring earlier; complications were reported in 5% versus 7.5% (with no tubectomy in the Galavit group despite ineffective therapy). The paper does not provide a specific limitation statement in the provided text beyond methodological details, and it does not address potential confounding beyond the stated group comparability and exclusions. Relevance to endometriosis: the article is about inflammatory pelvic-organ disease treatment rather than endometriosis, but it is included in this endometriosis/adenomyosis corpus because pelvic inflammatory processes affecting reproductive function are discussed as contributing to chronic pelvic pain and infertility, conditions that overlap conceptually with endometriosis-related symptom burdens.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Inflammatory diseases of women pelvic organs in reproductive period reach 60% among outpatients and 30% among inpatient gynecological patients. Aim. The aim of the study was to evaluate therapy effectiveness of women pelvic organs deseases with Galavit as part of combination therapy compared to standard treatment. Materials and methods. The study included 120 patients with diagnosis of inflammatory diseases of pelvic organs, randomized to 2 equal groups (n=60). In the main group, the patient in complex therapy received Galavit, according to the scheme: for 5 days, 100 mg intramuscularly 1 time per day, then 100 mg every 72 hours (No. 20); in the control group - only standard treatment. Results. Improvement of clinical condition (reduction of severity, normalization of body temperature, reduction of pain syndrome) in patients of the main group was observed 2 times faster than in patient of control group. Quickly resolve the signs of inflammation by ultrasound in the main group. The number of leukocytes, ESR, LII in the main group normalized faster than in patient of control group. On the background of treatment complications of inflammatory diseases of women pelvic organs was observed in 6 (5%) patients of the main group and 9 (7.5%) patients of the control group; aftercare of patients of the main group with ineffectiveness of therapy was achieved without tubectomy. The duration of treatment in the study group was 8±2.6 days us 10±3.9 days in the control group. Conclusion. The inclusion of Galavit in the complex therapy of inflammatory diseases of women pelvic organs accelerates relief of inflammation symptoms and reduces frequency of complications, which allows to preserve reproductive function. Galavit can be recommended for treatment inflammatory diseases of women pelvic organs.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (5)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK